Hi — I handle bulk & wholesale for this oil. Ask me anything, or tap a question below.
What the research says
More than a carrier. And we cite every word.
People reach for Bhringraj for more than one thing. Here’s what the published studies actually found — graded honestly, each one linked.
7
uses studied
14
papers cited
0
hidden from you
What the published studies found
Early evidence · 3 studies
Muscle Pain
Two preclinical animal studies (PMIDs 15022160, 22556819) show Eclipta alba (Bhringraj) ethanol extracts and alkaloids produce analgesic effects in rodent pain models (tail flick, tail clip, acetic acid writhing), and a narrative review (PMID 24191336) documents its traditional use as an analgesic. However, no human clinical trials exist, and none of the studies specifically examined muscle pain.
No human studies have evaluated Bhringraj (Eclipta alba) for sleep or insomnia; the only relevant evidence is a preclinical rat study that tested sedative activity but reported significant findings only for nootropic and anti-stress effects, while two hepatoprotection studies mention barbiturate-induced 'sleep time' purely as a liver function assay, not as a sleep outcome.
Only in vitro evidence exists for Bhringraj (Eclipta alba) against fungal infections: an isolated steroidal alkaloid showed good activity against Candida albicans, and plant extracts demonstrated significant antimicrobial activity against clinical fungal isolates (C. albicans, Aspergillus fumigatus) with MIC/MFC values of 31-500 μg/ml. No human clinical trials or RCTs have evaluated bhringraj for treating fungal infections.
Bhringraj (Eclipta alba) demonstrated hair-growth-promoting effects in an animal study, where topical petroleum ether extract stimulated hair matrix keratinocyte proliferation and downregulated TGF-β1 in nude mice (PMID 25484129). Traditional use for hair loss and graying is well documented in ethnopharmacological reviews (PMID 27355071), but no human clinical trials or RCTs appear in these results.
Evidence is limited to preclinical research: wedelolactone, a coumarin constituent of Eclipta alba (Bhringraj), reduced synovial inflammation, pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and cartilage damage in a mouse collagen-induced arthritis model via NF-κB/NLRP3 inflammasome inhibition. An ethnopharmacological review documents traditional use and general anti-inflammatory activity, but no human clinical trials for joint inflammation were identified.
The only relevant study found is a fish aquaculture trial (PMID 36836257) showing Eclipta alba (Bhringraj) leaf extract reduced cortisol and induced an 'anti-stress' response in catfish infected with a pathogen — this is a methanolic extract, not an essential oil, and the stress measured is infection-related physiological stress, not psychological anxiety. No human clinical trials, RCTs, or mammalian anxiolytic studies were identified in the provided results.
Only one small, uncontrolled Ayurvedic clinical study (31 patients) exists, in which Bhringaraja (Eclipta alba) was given orally as just one component of a multi-herb regimen (with Guduchi, Shirishadi Decoction, Cassia fistula purgation, and topical Snuhyadi Lepa) for vicharchika (eczema); it reported complete remission in 22.6% and recurrence prevention in 89.5%, but the effect cannot be attributed to Bhringraj alone and there are no RCTs, controlled trials, or monotherapy studies.
